http://www.zgazyw.com/Article/20240314214241-1364_1.html http://static.sse.com.cn/disclosure/listedinfo/bulletin/star/c/688177_20240209_2.pdf

百奥泰乳腺癌新药三期临床试验失败，再度敲响了新药研发风险 ...

http://www.huiyunyan.com/doc-dd96fc3eafe2eda02acce6b76a361ac3.html 웹2024년 12월 4일 · This is a multicenter, randomized, open-label, positive-controlled, superiority phase III clinical study. The object is to evaluate the safety and efficacy of BAT8001 for the … alexandria louisiana to dallas tx

百奥泰生物制药股份有限公司

웹2024年2月8日，百奥泰生物制药股份有限公司接连发布两条公告，第一条为该公司产品her2 adc药物bat8001的三期临床未达到与对照组（拉帕替尼联合卡培他滨）相比预设的优效目标；第二条公告为该公司宣布终止bat8001的临床试验，该药物累计研发投入2.26亿元。 웹During recent years, a number of new compounds against HER2 have reached clinics, improving the prognosis and quality of life of HER2-positive breast cancer patients. Nonetheless, resistance to standard-of-care drugs has motivated the development of novel agents, such as new antibody-drug conjugates (ADCs). The latter are a group of drugs that … 웹BAT8001 demonstrated promising efficacy in patients with advanced or metastatic HER2-positive breast cancer. In this heavily pretreated cohort with 76% of patients who relapsed … alexandria louisiana tv news